Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBITDA (2020 - 2025)

Tarsus Pharmaceuticals has reported EBITDA over the past 6 years, most recently at -$8.3 million for Q4 2025.

  • Quarterly results put EBITDA at -$8.3 million for Q4 2025, up 64.43% from a year ago — trailing twelve months through Dec 2025 was -$66.2 million (up 42.61% YoY), and the annual figure for FY2025 was -$66.2 million, up 42.61%.
  • EBITDA for Q4 2025 was -$8.3 million at Tarsus Pharmaceuticals, up from -$12.3 million in the prior quarter.
  • Over the last five years, EBITDA for TARS hit a ceiling of $10.4 million in Q1 2021 and a floor of -$41.9 million in Q4 2023.
  • Median EBITDA over the past 5 years was -$21.5 million (2022), compared with a mean of -$19.7 million.
  • Biggest five-year swings in EBITDA: soared 630.2% in 2021 and later tumbled 446.35% in 2023.
  • Tarsus Pharmaceuticals' EBITDA stood at -$14.9 million in 2021, then rose by 8.0% to -$13.7 million in 2022, then plummeted by 206.64% to -$41.9 million in 2023, then skyrocketed by 44.43% to -$23.3 million in 2024, then surged by 64.43% to -$8.3 million in 2025.
  • The last three reported values for EBITDA were -$8.3 million (Q4 2025), -$12.3 million (Q3 2025), and -$20.4 million (Q2 2025) per Business Quant data.